Press release
Still's Disease Treatment Market Poised for Significant Growth, Driven by Therapies Targeting Novel Pathways | DelveInsight
Still's Disease - Market Insight, Epidemiology And Market Forecast - 2032
DelveInsight's "Still's Disease - Market Insight, Epidemiology And Market Forecast - 2032 [https://www.delveinsight.com/report-store/stills-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report provides comprehensive insights into Still's disease, including historical and forecasted epidemiology, current treatment approaches, and emerging therapies across the 7MM. The report presents a detailed understanding of the disease, historical and forecasted epidemiology, current treatment paradigms, emerging therapies, and market dynamics that will shape the Still's disease landscape over the next decade.
Still's disease, encompassing both adult-onset Still's disease (AOSD) and systemic juvenile idiopathic arthritis (sJIA), is a rare autoinflammatory disorder characterized by persistent fever, typical salmon-colored rash, joint pain, and systemic inflammation. Recent research suggests these conditions may be part of a continuum of the same disease, prompting clinicians to seek unified approaches to diagnosis and management.
According to DelveInsight's latest market analysis, the Still's disease market is projected to expand significantly by 2032. The US leads the market, followed by EU4 and the UK, due to better healthcare infrastructure and higher awareness.
Download the Still's disease Market Forecast Report to understand which factors are driving the Still's disease therapeutic market @ Still's disease Market Trends [https://www.delveinsight.com/sample-request/stills-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
Still's disease epidemiological studies show that the total diagnosed prevalent cases of AOSD were approximately 2.5K in the US in 2023. Among the EU4 and the UK, Germany accounted for the highest number of diagnosed prevalent cases of AOSD, followed by France and the UK. Furthermore, the condition exhibits a bimodal age distribution, typically affecting individuals between 15-25 years and 36-46 years of age, with some studies indicating a higher prevalence among females.
Discover evolving trends in the Still's disease patient pool forecasts @ Still's disease Epidemiology Analysis [https://www.delveinsight.com/sample-request/stills-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
The current treatment landscape for Still's disease involves a stepwise approach, beginning with first-line therapies consisting of corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs), followed by second-line options including methotrexate or cyclosporin A. However, recent clinical evidence demonstrates promising results for biological drugs, particularly interleukin inhibitors. A systematic review and meta-analysis revealed that IL-1 inhibitors (IL-1i) and IL-6 receptor inhibitors (IL-6Ri) show the highest level of efficacy in managing Still's disease, with anakinra consistently ranked as the most effective intervention for achieving clinical responses. These biological therapies have demonstrated superior efficacy with favorable safety profiles, transforming the management approach for patients with limited treatment options.
The Still's disease pipeline contains several innovative therapies targeting novel pathways. Notable emerging treatments include Camoteskimab (CERC-007), a high-affinity, fully human anti-IL-18 monoclonal antibody being developed by Apollo Therapeutics. The first Phase Ib clinical trial of CERC-007 for AOSD commenced in May 2021, with the primary objective of determining safety, tolerability, and preliminary efficacy. Another promising candidate is Tadekinig alfa (r-hIL-18BP), a recombinant human interleukin-18 binding protein developed by AB2 Bio that inhibits the proinflammatory cytokine IL-18. Swedish Orphan Biovitrum's KINERET, an interleukin-1 receptor antagonist, is also under evaluation in a Phase III study for Still's disease treatment.
Recent clinical developments have underscored the therapeutic potential of targeting specific inflammatory pathways in Still's disease. In February 2025, the FDA granted Priority Review to Sobi's supplemental Biologics License Application for GAMIFANT for use in adults and children with hemophagocytic lymphohistiocytosis/macrophage activation syndrome associated with Still's disease, particularly in patients with inadequate response or intolerance to glucocorticoids, or with recurrent MAS. The target decision date (PDUFA) is June 27, 2025.
Discover evolving trends in the Still's disease treatment landscape @ Still's disease Recent Developments [https://www.delveinsight.com/sample-request/stills-disease-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].
Despite these advances, significant challenges remain in the Still's disease treatment landscape, including diagnostic delays due to the condition's rarity and symptom overlap with other inflammatory disorders. The most severe complication, Macrophage Activation Syndrome (MAS), affects approximately 10-15% of patients and is associated with high mortality rates. This complication, along with treatment-related adverse effects and high therapy costs, represents substantial unmet needs that emerging therapies aim to address.
Looking ahead, the Still's disease market is expected to witness continued innovation focused on targeted therapies, combination approaches, and personalized treatment strategies. As research further elucidates the molecular mechanisms underlying the disease, next-generation biologics and small molecules targeting specific inflammatory pathways are likely to reshape treatment paradigms, potentially improving long-term outcomes and quality of life for patients with this challenging condition.
Table of Contents
1. Key Insights
2. Executive Summary of Still's Disease
3. Competitive Intelligence Analysis for Still's Disease
4. Still's Disease: Market Overview at a Glance
5. Still's Disease: Disease Background and Overview
6. Still's Disease Patient Journey
7. Still's Disease Epidemiology and Patient Population
8. Still's Disease Treatment Algorithm, Current Treatment, and Medical Practices
9. Still's Disease Unmet Needs
10. Key Endpoints of Still's Disease Treatment
11. Still's Disease Marketed Products
12. Still's Disease Emerging Therapies
13. Still's Disease: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Still's Disease
17. KOL Views
18. Still's Disease Market Drivers
19. Still's Disease Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Related Reports:
Still's Disease Pipeline Insight [https://www.delveinsight.com/sample-request/stills-disease-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]
Still's disease Pipeline Insight provides comprehensive insights about the Still's disease pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Still's disease companies, including Swedish Orphan Biovitrum, R-Pharm International, LLC, Syneos Health, Apollo Therapeutics Ltd, and AB2 Bio, among others.
About DelveInsight
DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=stills-disease-treatment-market-poised-for-significant-growth-driven-by-therapies-targeting-novel-pathways-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Still's Disease Treatment Market Poised for Significant Growth, Driven by Therapies Targeting Novel Pathways | DelveInsight here
News-ID: 4013363 • Views: …
More Releases from ABNewswire
What Happens After the Promotion? Reynold Roberts Tells the Truth in "Help! I Ju …
Promotions are often treated like trophies. A reward. A pat on the back. A new title, a bigger desk, and-if you're lucky-a coffee mug with "Boss" on it. But what happens after the applause fades and you're actually expected to lead?
That's where Reynold Roberts steps in. In his refreshingly honest and eye-opening new book, HELP! I JUST GOT PROMOTED: Pitfalls of New Managers , Roberts doesn't hand out inspiration. He…
Click Media Lab: Markham SEO Company Driving Local Business Growth
Click Media Lab: Markham SEO Company Driving Local Business Growth
Every business, new or old, big or small, needs a presence on the internet. Markham is a growing market in Ontario. It offers a competitive climate for business and is a hub of technology. Nowadays, for your business to become more prominent among competitors, you need to put more effort than simply creating an attractive website. Your business needs exposure and…
NSCLC Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 10+ Com …
DelveInsight's, "Non-Small-Cell Lung Cancer Pipeline Insight 2025" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Non-Small-Cell Lung cancer (NSCLC) pipeline landscape. It covers the NSCLC pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NSCLC pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by…
CRISPR Clinical Trial Analysis: Key Insights into Rich Pipeline Featuring 25+ Co …
DelveInsight's, "CRISPR Therapies Pipeline Insight, 2025," report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in CRISPR Therapies pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore the comprehensive insights by DelveInsight and stay ahead in understanding…
More Releases for Disease
Biopharmaceutical Fermentation Market 2022 | Growing Morbidity of Genetic Diseas …
According to Precision Business Insights (PBI), the latest report, the biopharmaceutical fermentation market is expected to be valued at USD 10,302.1 million in 2022, growing at a 4.7% CAGR from 2022 to 2028. The growing prevalence of chronic illness, cancer, cardiac diseases, infectious diseases, antibiotic resistance, autoimmune diseases, etc., globally causes the leaning toward biopharmaceutical products, which show promising results in the research studies. Moreover, new findings by the…
Global Inflammatory Bowel Disease (IBD) Market Key Players Analysis, Disease Ind …
Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn’s Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol…
Refsum Disease Industry An Overview of A New Disease - 2018
"Refsum Disease" is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene…
Gaucher Disease Treatment Market, by Disease Type, Therapy Type
Gaucher disease is an autosomal recessive inherited metabolism disorder where a type of fat (lipid) called glucocerebroside is unable to degrade. Body synthesis enzyme called glucocerebrosidase, which breakdowns and reprocesses glucocerebroside. Gaucher disease is caused by mutations of a single gene called GBA, which leads to very low levels of glucocerebrosidase enzyme leading to low degradation of glucocerebroside. There are three types of Gaucher disease namely: type 1, type 2,…
Autoimmune Disease Diagnostic Market By Disease, Tests Type, Regions, Companies
"The Latest Research Report Autoimmune Disease Diagnostic Market, Global Forecast, By Disease, Tests Type, Regions, Companies provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
Autoimmune Disease Diagnostic Market is anticipated to exceed US$ 18 Billion, experiencing a significant growth over the forecast period. Autoimmune diseases take place when there is disruption of the usual control process (immune system of the body becomes…
Chagas Disease (Infectious Disease) Pipeline Forecast Report, H1, 2017 [MRH]
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease Market (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and…
